Class 4 Medicines Defect Information: Orifarm UK Ltd, Concerta XL 18mg & 36 mg prolonged release tablets, EL (24)A/07
Orifarm UK has informed the MHRA of an error with the Patient Information Leaflet (PIL) packaged within the parallel import packs of the specific batches of Concerta XL 18mg and 36mg prolonged release tablets mentioned in this notification.
MDR number
MDR 060-02/24
Company name
Orifarm UK Ltd
Product name
Concerta XL 18mg prolonged release tablets, PLPI 46927/0226 & 46927/0227
| Batch No | Expiry Date | Pack Size | First Distributed |
|---|---|---|---|
| 3EE35801 | 31/01/2026 | 30 tablets | 03/11/2023 |
| 3EE35802 | 31/12/2025 | 30 tablets | 03/11/2023 |
| 3EE36101 | 31/01/2026 | 30 tablets | 09/11/2023 |
| 3EE35803 | 31/12/2025 | 30 tablets | 06/12/2023 |
| 3EE36102 | 31/01/2026 | 30 tablets | 14/12/2023 |
| 3FE46100 | 28/02/2026 | 30 tablets | 02/01/2024 |
| 3FE46101 | 28/02/2026 | 30 tablets | 08/01/2024 |
| 3GE51900 | 28/02/2026 | 30 tablets | 24/01/2024 |
Concerta XL 36mg prolonged release tablets, PLPI 46927/0062 & 46927/0207
| Batch No | Expiry Date | Pack Size | First Distributed |
|---|---|---|---|
| 3AE07102 | 28/02/2026 | 30 tablets | 06/11/2023 |
| 3DE29500 | 28/02/2026 | 30 tablets | 09/11/2023 |
| 3FE44101 | 30/09/2025 | 30 tablets | 23/11/2023 |
| 3FE44102 | 31/01/2026 | 30 tablets | 23/11/2023 |
| 3AE07103 | 31/12/2025 | 30 tablets | 07/12/2023 |
| 3DE29201 | 30/09/2025 | 30 tablets | 14/12/2023 |
| 3DE29501 | 31/01/2026 | 30 tablets | 14/12/2023 |
| 3FE44103 | 28/02/2026 | 30 tablets | 18/12/2023 |
| 3FE46800 | 31/03/2026 | 30 tablets | 11/01/2024 |
| 3FE46801 | 31/03/2026 | 30 tablets | 17/01/2024 |
| 3EE37002 | 31/01/2026 | 30 tablets | 17/01/2024 |
Concerta XL 36mg prolonged release tablets, PLPI 46927/0063
| Batch number | Expiry date | Pack size | First distributed |
|---|---|---|---|
| 3GE50002 | 28/02/2026 | 30 tablets | 17/01/2024 |
Active Pharmaceutical Ingredient: Methylphenidate Hydrochloride
Brief description of the problem
Orifarm UK has informed the MHRA of an error with the Patient Information Leaflet (PIL) packaged within the parallel import packs of the above batches of Concerta XL 18mg and 36mg prolonged release tablets. A section of the product side effects containing the serious side effects has been added to paragraph 3 in error however this should be part of paragraph 4. All other sections of the PIL are unaffected.
Advice for healthcare professionals
Healthcare professionals are advised to inform patients of this discrepancy when dispensing packs from the specified batches.
Advice for patients
Patients do not need to take any action. This issue is about an error in the patient information leaflet that accompanies the above specified batches of Concerta XL18mg and 36mg prolonged release tablets. Some information on the side effects is incorrectly included in paragraph 3 instead of paragraph 4. The quality of the medicine is not affected.
Patients who experience adverse reactions or have any questions about the medication should seek medical attention. Any suspected adverse reactions should also be reported via the MHRA Yellow Card scheme.
Further Information
For medical information and stock control queries please email jacook@Orifarm.com, or telephone 01923 204333.
Recipients of this Medicines Notification should bring it to the attention of relevant contacts by copy of this notice. NHS regional teams are asked to forward this to community pharmacists and dispensing general practitioners for information.
Yours faithfully
Defective Medicines Report Centre
10 South Colonnade
Canary Wharf
London
E14 4PU
Telephone +44 (0)20 3080 6574
Download document